Drugs / Spheramine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00206687 | Jan 2003 → May 2012 | Parkinson disease | Bayer | Terminated | Missed primary |
| Phase 2 | NCT00761436 | Feb 2000 → May 2012 | Parkinson disease | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spheramine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00761436 ↗ |
| Known as | BAY86-5280 | “Spheramine (BAY86-5280)” NCT00761436 ↗1“Spheramine (BAY86-5280)” NCT00206687 ↗ |
| Modality | Cell therapy | “cell transplantation” PMID 21565557 ↗ May 2011 |
| Route | Other | “Bilateral implantation of Spheramine into the postcommissural putamen” NCT00206687 ↗ |